Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 71
Selected: 0
NCT IDTitle
NCT02805660Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
NCT04887870Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
NCT03994796Genetic Testing in Guiding Treatment for Patients With Brain Metastases
NCT03575598Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
NCT00975767A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
NCT05924152A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
NCT00324194A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
NCT04772612A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
NCT06130254Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
NCT03680521Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
NCT00323934Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT04518046Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
NCT04418661Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
NCT04123704Sitravatinib in Metastatic Breast Cancer
NCT05868356A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib
NCT02236195Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
NCT05853575Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT00697632Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
NCT02954991Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
NCT00431873A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
NCT05255276PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.
NCT03785249Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT05840510Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
NCT05178888Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
NCT00666497Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT02993991Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
NCT02117245Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers
NCT05634525Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
NCT04800614A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib
NCT05542342Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
NCT02664935National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
NCT06026410KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT05419817Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
NCT00324220A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
NCT03606174A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
NCT05609578Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT02018926Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
NCT04330664Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
NCT00358982Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT05848843A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
NCT05578092A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
NCT04925986Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
NCT04935112A Study to Explore the Effect of Acid-reducing Agents
NCT02544633Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
NCT00679133Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies
NCT05737706Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
NCT05263986The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
NCT00372437A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
NCT06248606Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
NCT00511576Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors